CPR Provides Fast, Affordable Repairs for Phones, Tablets, Laptops and Game Consoles

INDEPENDENCE, OH / ACCESSWIRE / April 25, 2019 / CPR – Cell Phone Repair (CPR), the world’s largest mobile device repair network, is pleased to announce that it has consummated an investment in iRiparo, an Italian mobile device repair company with more than 185 franchised repair stores in Italy, France, Belgium, Switzerland and Spain. iRiparo is now jointly owned by its founder, Carlo Alberto Rolando, CPR and Prink, an Italian company with more than 1,300 franchised ink cartridge and office supply retail stores located throughout Europe.

To learn more about CPR – Cell Phone Repair and the services that they offer, please check out https://www.cellphonerepair.com/.

Josh Sevick, CPR’s CEO, stated, “We are very excited to become partners with Carlo and the owners of Prink. They have a proven track record of developing successful retail operations throughout Europe and have expert knowledge of how to effectively operate throughout the European Union (EU). With the investment in iRiparo, CPR store network now has more than 750 stores doing business in 17 countries. Developing a global company that can service multi-national, device manufacturers, wireless and warranty companies is a major goal for us and the iRiparo transaction is big a step forward in that regard. By year-end, we plan to grow our store network to more than 900 stores operating in 20 countries.”

In conjunction with CPR’s investment in iRiparo, CPR’s affiliated parts distribution company, Mobile Defenders, is entering into a joint venture with iRiparo and Gruppo AQA, a distribution company based in Italy, to develop a parts distribution operation in Europe. Jordan Notenbaum, Mobile Defender’s CEO, stated, “We have been looking for the right opportunity to expand into Europe and we feel very confident that this is a terrific opportunity to leverage our 10 years of experience in the mobile phone parts business. AQA has extensive experience as a European distribution company and iRiparo, in partnership with CPR, plans to become the largest mobile phone retail repair company in the EU.”

Carlo Alberto Rolando, iRiparo’s founder and CEO, stated, “For the past year, I have been speaking with the CPR and Mobile Defenders teams about the benefits of working together. I am delighted that we were able to come to terms and form our new partnerships. I think these will be mutually beneficial, long-term relationships.”

About CPR Cell Phone Repair:

Founded in Orlando, Fla. in 1996, CPR Cell Phone Repair is the fastest growing wireless technology franchise in North America and operates over 750 locations. As a pioneer and leader in the electronics repair industry, CPR offers same-day repair and refurbishing services for cell phones, laptops, gaming systems, digital music players, tablets, and other personal electronic devices. For four straight years, CPR was named in Entrepreneur Magazine’s Franchise 500 List. In 2019, CPR was ranked in the top 25 of the list and placed as the number one business for tech business franchises. For more information about CPR Cell Phone Repair and franchise opportunities, visit https://www.cellphonerepair.com/ or call 877-856-5101.

Contact:

Josh Sevick

jsevick@merrymtg.com

877-856-5101

SOURCE: CPR Cell Phone Repair

ReleaseID: 543004

MARTINSVILLE, NJ / ACCESSWIRE / April 25, 2019 / The new 11th Edition of The Robo Report™ published by Backend Benchmarking covering the first quarter of 2019 doesn’t pull any punches in its critique of moves by robo advisors as it continues to bring transparency to the space. SoFi is at the center of a questionable move selling Vanguard funds to invest in their own similar funds and incurring a big capital gains tax on investors without an opt-out option or prior notice, says BackendB Founder Ken Schapiro.

”I fail to see how SoFi was acting in their clients’ best interest in swapping funds for their own. It’s going to take me 35 years to make up the capital gains tax hit. This is why our quarterly report to investors in the financial digital advice sector is so important. Investors need to know what is being done at these firms in regard to managing their assets as a fiduciary. Although their platform has a suite of undeniably compelling products, we question whether their customers are their top priority,” said Mr. Schapiro.

Highlights of the New First Quarter 2019 Robo Report(TM):

Fidelity Go and SigFig emerging as two-year and three-year performance leaders.
Schwab’s fixed income perform at the top of the group for the three-year period.
Year-to-date performance led to many new names on the leader-board.
Swell led the IRA universe by a wide margin.
iQvestment, an actively managed portfolio and one of the new that hold individual securities, led the equity performance for the first quarter.

”Schwab’s transition to subscription-based pricing for their hybrid robo product made waves last quarter. Many are questioning whether Schwab’s new subscription pricing will usher in a paradigm shift in the way financial advice is paid for in the U.S.,” said David Goldstone, Senior Research Analyst for the Report.

”Acorns, Personal Capital, Nutmeg, and Ellevest raised a combined nearly $250 million in capital this quarter, proving there is an appetite for investing in established digital advice players,” said Mr. Goldstone.

This quarter he published an in-depth interview with Karen Wimbish, Head of Product for U.S. Bancorp Investments and Financial Planning, about her experience with Intuitive Investor, U.S. Bank’s digital investing platform.

Some takeaways:

Digital advice is a solution for self-directed investors who would prefer not to manage their own investments.
Industry professionals have learned that most people are not quite ready to invest without some level of human guidance.
Robo advice products are finding success with clients before they are ready or attractive to full-service advisors.

The Report ranks the top three robos by performance in Equity, Fixed Income, and Total Portfolio as well as historical performance since each accounts’ inception.

Backend Benchmarking opened and funded portfolios seeking a similar asset allocation to allow for comparison. The knowledge of the underlying assets held helps to understand the structure of the portfolio, the risk, and what is driving performance.

The Robo Report™ is available for free at https://www.backendbenchmarking.com/the-robo-report/. Follow the Report on Twitter @theroboreport.

Please see this link for Terms of Use Guidelines for subscribing or using data: https://www.backendbenchmarking.com/the-robo-report/use-guidelines/

Failure to comply with the guidelines may result in a takedown notice, revocation of your subscription to Our Research, and/or legal action.

To request written consent or a license, contact The Company at info@backendb.com or call 732-893-8290 and ask for David Goldstone.

Disclaimer of Warranties:

Research is provided “as is” with all faults. The Company disclaims all warranties of any kind regarding the Research, either express or implied, including but not limited to, any implied warranty of merchantability, fitness for a particular purpose, ownership, noninfringement, accuracy of informational content, and absence of viruses and damaging or disabling code.

The Company does not warrant the accuracy, completeness, or timeliness of the Research. The Company shall not be responsible for investment decisions, damages, or other losses resulting from use of Our Research.

Past performance does not guarantee future performance. The Company shall not be considered an “expert” under the Securities Act of 1933. The Company does not warrant that this service complies with the requirements of the FINRA or any similar organization or with the securities laws of any jurisdiction.”

Some jurisdictions do not allow the exclusion or limitation of implied warranties, so the above exclusions or limitations may not apply.

Please direct media inquiries to:

Bill Bongiorno
President
Blue Chip Public Relations, Inc.
914-533 – 7065
www.bluechippr.com
Bill@bluechippr.com

SOURCE: Backend Benchmarking

ReleaseID: 542972

MIDLAND, VA / ACCESSWIRE / April 25, 2019 / Easi-Set Worldwide, a subsidiary of Smith-Midland Corporation (OTCQX: SMID), announced that it received approval from The California Department of Transportation for its MASH TL3 tested J-J Hooks temporary restrained (pinned or bolted) precast concrete safety barrier.

This marks the first penetration of the J-J Hooks brand into California, the 2nd largest market in the U.S. with over 26 million drivers and almost 400,000 lane miles of roadway.

The barrier, in 12.5-foot lengths, sustained dynamic deflections of 5.9-inches when bolted (using only two bolts) and 8.8-inches when pinned (using three pins). The restrained design received FHWA Federal Aid Eligibility Letters B 52B and B 52C respectively.

J-J Hooks offers state/provincial transportation authorities a family of MASH TL3 tested temporary precast concrete barrier for immediate use on their roadways. Available are two free-standing tested designs (12-foot & 20-foot lengths) and the restrained (bolted or pinned) design described above.

Thirty-four state/provincial authorities have approved J-J Hooks restrained barrier, as an alternate to their standard barrier, for use on their roadways. Additional approvals have been requested and are expected shortly.

To date, nearly 15,000,000 LF of J-J Hooks have been provided to state construction projects worldwide, including 500,000 LF of MASH approved barriers. All J-J Hooks barrier designs utilize the same J-Hook connection system which provides the industry’s fastest installation and removal capability, has integral self-aligning connection guides, and requires no loose hardware. Visit www.JJHooks.com for more information.

Easi-Set Worldwide, a wholly-owned subsidiary of Smith-Midland Corporation, a public company, licenses the production and sale of Easi-Set products and provides diversification opportunities to the precast industry worldwide. For more information on Easi-Set precast concrete products or licensing opportunities, please contact Easi-Set by calling 1-800-547-4045 or going online to www.EasiSet.com.

Media, Licensing and Sales Inquiries:

info@easiset.com
(540) 439-8911

SOURCE: Smith-Midland Corporation

ReleaseID: 542951

PRINCETON, NJ / ACCESSWIRE / April 25, 2019 / With a lecture yesterday at the Rutgers-Princeton Center for Computational Cognitive Neuropsychiatry, Dr. Jay Phoenix Singh, 32, has become the first psychologist to lecture at all eight Ivy League universities (Harvard, Yale, Princeton, Columbia, Dartmouth, Brown, Cornell, and the University of Pennsylvania) as well as both Oxbridge Universities (Oxford and Cambridge).

The lecture presented yesterday at Princeton University was entitled Psychiatry & Violence: Biological & Psychosocial Assessment and focused on the complex relationship between mental health and violence. Much attention has been paid to this relationship in recent years, with the number of secure inpatient beds in psychiatric hospitals on the rise and surveys of the criminal justice system establishing prisons and jails as the largest providers of mental healthcare in the United States. Hence, establishing valid and reliable methods of identifying patients who will commit violent acts has become an important health and safety issue. The lecture discussed current evidence-based methods of assessing violence risk in psychiatric populations, including both biological and psychosocial methods.

Dr. Singh is a Fulbright Scholar, Clinical Associate in the Department of Psychiatry at the University of Pennsylvania, and Visiting Scholar at the Institute of Criminology at Cambridge University. The internationally award-winning Founder of the Global Institute of Forensic Research (successful 2017 exit as CEO), he was named the youngest tenured Full Professor in Norway in 2014 and served as Senior Clinical Researcher in Forensic Psychiatry and Psychology for the Department of Justice of Switzerland. Since completing his doctoral studies in psychiatry at the University of Oxford and clinical psychology at Universitat Konstanz, he has authored over 75 peer-reviewed articles and books and has been the recipient of awards from organizations including the American Psychological Association, the American Board of Forensic Psychology, the Royal College of Psychiatrists, the European Congress on Violence in Clinical Psychiatry, the Society for Research in Child Development, and the Society for Research in Adolescence. He currently serves as Chief Data Scientist for OpinionMeter International, as a Consultant for Rezon8 Capital & Advisory Group, and as Founder and CEO of The Model Man.

When asked for comment, Dr. Singh stated: ”I have called this six-year journey my ‘Academic Everest’. I am deeply grateful for the opportunities afforded to me by colleagues, both old and new, to not only spread awareness of my research in the field of behavioral health at this elite level but also to encourage fellow Millennial academics embrace their individuality and pursue their international goals.”

About Rezon8 Capital & Advisory Group

Rezon8 Capital & Advisory Group is a private equity firm based in Reston, Virginia, whose primary objective is to partner with founders and CEOs of technology-driven service companies at various stages in their growth cycles and across different industries. Rezon8 differentiates itself by investing its own capital as well as providing strategic and operational expertise to accelerate each portfolio company’s growth and profitability. For more information, visit www.rezon8capital.com.

MEDIA CONTACT

info@rezon8capital.com

SOURCE: Renzon8 Capital & Advisory Group LLC

ReleaseID: 542975

SAN FRANCISCO, CA / ACCESSWIRE / April 25, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (”Jaguar” or the ”Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company is donating a supply of Mytesi®, the FDA-approved drug product of Jaguar’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (”Napo”), to Direct Relief, a Santa Barbara, California-based humanitarian aid organization.

Mytesi (crofelemer 125 mg delayed-release tablets) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Active in all 50 states and more than 80 countries, Direct Relief is dedicated to improving the health and lives of people affected by poverty or emergencies – without regard to politics, religion, or ability to pay. Direct Relief was named No. 1 on Charity Navigator’s 2017 list of the ”10 Best Charities,” which accounts for financial performance, transparency, and accountability.

”This donation reflects Jaguar’s ongoing commitment to enhance Mytesi access for people living with HIV—across all populations, all countries, regardless of social or economic status,” stated Lisa Conte, president and chief executive officer of Jaguar.

”This very welcome donation will support Direct Relief’s efforts to provide supportive care to HIV patients in need,” commented Maris Steward, Direct Relief Corporate Engagement.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute ”forward-looking statements.” These include statements regarding the expectation that Jaguar will donate a supply of Mytesi to Direct Relief. In some cases, you can identify forward-looking statements by terms such as ”may,” ”will,” ”should,” ”expect,” ”plan,” ”aim,” ”anticipate,” ”could,” ”intend,” ”target,” ”project,” ”contemplate,” ”believe,” ”estimate,” ”predict,” ”potential” or ”continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health

SOURCE: Jaguar Health, Inc.

ReleaseID: 542960

Experienced Business Transformation Executive Joins Collaborative Business Information Services Leader

MEDIA, PA / ACCESSWIRE / April 25, 2019 / Trust Exchange, the leader in Collaborative Business Information Services, today announced that the company has appointed Randy Bradley to its Board of Directors.

Mr. Bradley brings a wide range of experience to Trust Exchange spanning financial services, eCommerce, and retail. Presently a Managing Director at BMS, LLC and Operating Partner at Ames Watson, Mr. Bradley brings more than two decades of experience to Trust Exchange having held leadership roles in technology, strategy, digital business transformation, and operations at leading companies including eBay, GSI Commerce, Broadridge Financial, Lids Sports Group and Gruntal & Co., LLC.

Mr. Bradley joins as Trust Exchange accelerates its disruption of the $40B market for Business Information Services using an innovative approach to compliance and vendor management designed for the digital age and powered by the cloud. The company recently achieved Advanced Technology Partner status in the Amazon Web Services (AWS) Partner Network, validating both the advanced technology and client value delivered by the Trust Exchange Platform.

”Randy’s exceptional pedigree in technology and financial services is a perfect fit for Trust Exchange,” said Ed Sullivan, Founder and CEO of Trust Exchange. ”His deep experience in strategy, operations, and business transformation will be essential as we expand our business and continue to prove for our clients that today’s compliance challenges can no longer be addressed with yesterday’s legacy business information services.”

”Trust Exchange has a bold vision to transform compliance and operational processes with an innovative platform that streamlines processes and delivers network benefits for vendors, compliance officers, auditors, and more,” said Randy Bradley, Vice Chairman of the Board at Trust Exchange. ”The Trust Exchange Platform helps companies on both sides of any business relationship work together without the cost and friction of compliance, and I couldn’t be more excited to join the team to advance its vision.”

To learn more about Trust Exchange and to join for free, visit https://web.trustexchange.com/register.php.

About Trust Exchange

Trust Exchange is disrupting the $40B Business Information Services market by enabling companies to securely disclose and monitor key information about customers, vendors, and partners with a centralized, secure cloud platform. Trust Exchange provides Collaborative Compliance, dramatically lowering the cost of compliance by helping institutions automate critical compliance activities, build deeper trust with customers, vendors, and partners, and monitor their own company’s reputation performance over time.

For more information, visit www.trustexchange.com.

Follow @b2btrust on Twitter

Follow Trust Exchange in LinkedIn at https://www.linkedin.com/company/15218284/
Read the Trust Exchange blog at http://www.trustexchange.com/blog/
Become a fan of Trust Exchange on Facebook: https://www.facebook.com/TrustExchange/

CONTACT:

Ed Sullivan
Trust Exchange
edsull@trustexchange.com

SOURCE: Trust Exchange

ReleaseID: 542991

SACRAMENTO, CA / ACCESSWIRE / April 25, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office. The invention is titled “CBD Formulations to Treat Peptic and Gastrointestinal Ulcers”.

The pharmaceutical and OTC drug markets to treat ulcers is one of the largest medical markets in the United States. Approximately 4% of all adult Americans suffer from peptic (also called gastrointestinal) ulcers. Peptic ulcers can occur in the stomach, the intestines and even parts of the esophagus. This invention covers all non-cancerous ulcers that occur in the stomach, the intestines and even parts of the esophagus. The most common causes of peptic ulcers are infection with the bacterium Helicobacter pylori (H. pylori) and long-term use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) (Advil, Aleve, others).

The provisional patent application number is 62838236. At this time, Falcon will not reveal any details about the provisional patent application except for the fact that the formulation contains CBD and an off-patent ingredient from one of the most well known and well-documented healthcare products in the entire world. The purpose and goal of the patent is to secure patent protection now to operate in what is another multi-billion-dollar market.

This provisional patent application follows Falcon’s recent provisional patent application to treat acne with certain CBD formulations. The latest provisional patent application continues Falcon’s strategy to gain advantages over potential competition. These advantages may be marketing and sales advantages or formulation advantages such as the one covered by this provisional patent application.

William J. Delgado, Chairman and Chief Executive Officer of Falcon Technologies stated, “We are ecstatic that we can deliver this great news to our shareholders. We are working diligently to gain an advantage over the other companies currently selling CBD products and this second provisional patent application is another example of the progress we are making with our overall corporate strategy.”

CBD ( Cannabidiol ) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess a variety of therapeutic properties.

About Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.)

Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) is a nutraceutical company developing a range of CBD-based products. The company’s mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.

CBD Disclaimer

The statements made regarding CBD products including our future products have not been evaluated by the Food and Drug Administration. The efficacy of these products and the testimonials made have not been confirmed by FDA- approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: William J. Delgado
(775) 443-4740
djwllc@hotmail.com

SOURCE: Falcon Technologies

ReleaseID: 543003